PF-04457845 – Kodiac biolabs

Plain-language summaryIntrigue 64 / 100

PF-04457845 is the most thoroughly studied FAAH inhibitor in humans, developed by Pfizer to raise endogenous anandamide as a non-cannabinoid approach to pain and anxiety. Phase 1 and 2 trials in osteoarthritis and fibromyalgia produced disappointing efficacy, and the compound is best remembered for its association with the 2016 Bial trial disaster in France, where a different FAAH inhibitor (BIA 10-2474) caused one death and severe neurological injury in five healthy volunteers. Subsequent investigation found the Bial compound had broad off-target lipase activity that PF-04457845 lacks, and the FAAH approach itself was not implicated. PF-04457845 is now being studied for cannabis use disorder. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

54/100

The canonical clinical-stage FAAH inhibitor, strong probe value but modest clinical payoff so far

Look, if you’re working anywhere near the endocannabinoid system, PF-04457845 is the compound you reach for. Not because it’s the flashiest thing in the library, but because it’s the cleanest, most human-validated FAAH inhibitor we have. Pfizer’s covalent piperidine-urea scaffold gives you irreversible, highly selective FAAH inhibition with a ~14-hour plasma half-life, verified target engagement in humans, and a pharmacokinetic profile that actually translates from preclinical models. Thats a short list of compounds that can claim all three.

The mechanism is worth thinking through carefully. FAAH inhibition doesn’t force receptor agonism the way a direct CB1 agonist does. Instead, it elevates the endogenous pool of N-acylethanolamides: anandamide hitting CB1/CB2 and TRPV1, OEA and PEA acting primarily through PPARs and GPR119. You get a diffuse, physiological-range modulation of multiple pathways from a single enzyme knockout. On paper, that’s elegant. The CNS penetration is real, the peripheral bioavailability is solid, and the selectivity over other serine hydrolases is among the best documented in the class.

Here’s the thing though: the clinical results have been disappointing in the indications where FAAH inhibition seemed most obvious. The 2012 Huggins et al. phase 2 in osteoarthritis pain showed clear target engagement and almost no signal on the primary endpoint. Fibromyalgia data fared similarly. What we don’t know is whether that reflects the mechanism, the compound, the indication selection, or something about how endocannabinoid tone works in chronic pain states versus acute models. That ambiguity is scientifically interesting even if its commercially discouraging.

The shadow of the 2016 Bial tragedy is worth addressing directly. BIA-10-2474, the FAAH inhibitor that killed one volunteer and injured five others in Rennes, was a different compound with different off-target liabilities. Post-incident analysis placed the blame on BIA-10-2474’s promiscuous serine hydrolase inhibition profile, not the FAAH inhibition mechanism itself. PF-04457845’s selectivity data held up under scrutiny. The tragedy did, however, cast a long institutional shadow over the class and almost certainly slowed clinical development timelines industry-wide.

Where we think PF-04457845 earns its place in a research library is as a translational probe. The recent cannabis use disorder work is genuinely more interesting than the pain programs, and the rationale for FAAH inhibition in addiction biology is mechanistically distinct enough to be worth watching. For investigators studying the ECS, comparing FAAH inhibitor selectivity profiles, or benchmarking against other endocannabinoid-elevating strategies, this is the reference compound. Its not a frontier molecule, and the bench scientist who wants the next big thing will find more novelty elsewhere. But if you’re asking whether FAAH inhibition does what you think it does in a human being, PF-04457845 is how you find out.

Novelty: 42
Mechanism promise: 52
In-category differentiation: 62
Evidence quality: 57
Translational signal: 45
Research bench value: 70

Rationale PF-04457845 sits at a curious intersection: it’s the most thoroughly human-characterized compound in its class and a genuine reference probe for FAAH biology, but the class has persistently underdelivered on pain efficacy and the translational signal outside cannabis use disorder remains soft. Differentiation within FAAH inhibitors is high; differentiation against the broader pain/ECS research landscape is less convincing.

Selective FAAH inhibitor (clinical-stage)

A clinical-stage FAAH inhibitor; the most thoroughly studied FAAH inhibitor in human trials, including a tragic phase 1 fatality at Bial.

Abstract

PF-04457845 (CAS 1020315-31-4; molecular formula C20H21F3N4O3; molecular weight 422.40) is a covalent piperidine-urea FAAH inhibitor developed at Pfizer. The compound is selective for FAAH over other serine hydrolases and produces elevated plasma and brain N-acylethanolamides (anandamide, OEA, PEA) at clinical doses. Phase 1 and 2 clinical trials in osteoarthritis pain, fibromyalgia, and (more recently) cannabis use disorder have demonstrated FAAH target engagement and modest clinical effects in some indications. The compound is most associated with the broader FAAH inhibitor scrutiny following the 2016 Bial Pharmaceuticals tragedy in Rennes, where a different FAAH inhibitor (BIA-10-2474) caused one death and severe neurological injury in a phase 1 trial; the cause was attributed to off-target effects unique to BIA-10-2474, exonerating PF-04457845 specifically. Plasma half-life is approximately 14 hours. Used as the canonical clinical-stage FAAH inhibitor for translational research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-329Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.